THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. Use of a substance P receptor antagonist which is a NK1 receptor antagonist in the preparation of a medicament for preventing and/or treating a disease, condition or state associated with chronic traumatic encephalopathy.

2. A use according to claim 1, wherein the disease, condition or state is due to tau hyperphosphorylation associated with chronic traumatic encephalopathy.

3. A use according to claim 1, wherein the NK1 receptor antagonist is selected from one or more of the group consisting of Casopitant, CGP49823, CP-122,721, CP-96,345, CP-99,994, FK 888, GR 82334, GR 94800, GR203040, GR-205171, GSK1144814, GSK206136, GSK424887, GW679769, HSP-117, L 703,606, L 732,138, L 733,060, L 742,694, L668,169, LY 303241, LY 303870, LY 306740, Maropitant, MEN 11149, Orvepitant, PD 154075, R-544, RP-67580, RPR 100893, SCH619734, Spantide II, Spantide III, Spendide, SR140333, Vestipitant, WIN-41,708, WIN-62,577, or a pharmaceutically acceptable salt or a tautomer thereof.

4. A use according to any one of claims 1 to 3, wherein the substance P receptor antagonist which is a NK1 receptor antagonist is to be administered to the subject at a dose of 0.25 mg/kg to 25 mg/kg.

5. A use according to any one of claims 1 to 4, for reducing progression of the disease, condition or state associated with chronic traumatic encephalopathy.